Combination of HER2-Targeted Antibodies (Trastuzumab plus Pertuzumab) is Effective Against HER2 Amplified Ovarian Cancer Xenograft Models

被引：0
|
作者：
Langdon, S. P. [1 ]
Sims, A. H. [1 ]
Harrison, D. J. [2 ]
机构：
[1] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[2] Univ St Andrews, St Andrews, Fife, Scotland
来源：
JOURNAL OF PATHOLOGY | 2013年 / 231卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [31] Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo
    Nonagase, Yoshikane
    Yonesaka, Kimio
    Watanabe, Satomi
    Haratani, Koji
    Takahama, Takayuki
    Takegawa, Naoki
    Ueda, Hiroto
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakamoto, Haruka
    Tamura, Takao
    Nakagawa, Kazuhiko
    Tsurutani, Junji
    CANCER RESEARCH, 2016, 76
  • [32] HER2 antibodies pertuzumab and trastuzumab differ in their effect on cell signaling and growth inhibition in breast cancer cells
    Le, Xiaofeng
    Mao, Weiqun
    Lu, Yiling
    Mills, Gordon B.
    Bast, Robert C., Jr.
    CANCER RESEARCH, 2006, 66 (08)
  • [33] Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
    Xiao, Yi
    Ding, Jiahan
    Ma, Dachang
    Chen, Sheng
    Li, Xun
    Yu, Keda
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [34] Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03
    Yamashita, Toshinari
    Kawaguchi, Hidetoshi
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Function of a HER2 VUS in colorectal cancer with APC mutations and its potential for HER2-targeted therapy
    Mitani, Yosuke
    Ohashi, Shinya
    Kikuchi, Osamu
    Muto, Manabu
    ANNALS OF ONCOLOGY, 2023, 34 : S1455 - S1455
  • [36] HER2 and ovarian cancer
    Sarancone, S.
    Acosta Haab, G.
    Nocito, A.
    Frahm, I
    Lupo, E.
    Caceres, V
    VIRCHOWS ARCHIV, 2009, 455 : 13 - 13
  • [37] Screening for HER2 alterations and HER2-targeted therapy in non-small cell lung cancer
    Kinoshita, Ichiro
    ANNALS OF ONCOLOGY, 2015, 26 : 40 - 40
  • [38] HER2-targeted antibody drug conjugates for ovarian cancer therapy
    Jiang, Jing
    Dong, Lihou
    Wang, Lei
    Wang, Ling
    Zhang, Jing
    Chen, Fang
    Zhang, Xiuli
    Huang, Min
    Li, Shenjun
    Ma, Weiwei
    Xu, Qiaoyu
    Huang, Changjiang
    Fang, Jianmin
    Wang, Chunhua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 93 : 274 - 286
  • [39] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [40] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
12345